Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Corteva CTVA in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 8 | 3 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 1 | 0 | 2 | 0 | 0 |
| 3M Ago | 0 | 8 | 1 | 0 | 0 |
Analysts have recently evaluated Corteva and provided 12-month price targets. The average target is $59.92, accompanied by a high estimate of $67.00 and a low estimate of $50.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 13.37%.
Deciphering Analyst Ratings: An In-Depth Analysis
The analysis of recent analyst actions sheds light on the perception of Corteva by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Joshua Spector | UBS | Lowers | Buy | $64.00 | $65.00 |
| Aron Ceccarelli | Berenberg | Lowers | Hold | $52.00 | $63.00 |
| Brian Wright | Roth MKM | Lowers | Buy | $63.00 | $82.00 |
| Benjamin Theurer | Barclays | Lowers | Equal-Weight | $50.00 | $66.00 |
| Arun Viswanathan | RBC Capital | Lowers | Outperform | $56.00 | $61.00 |
| Vincent Andrews | Morgan Stanley | Lowers | Overweight | $60.00 | $80.00 |
| Aleksey Yefremov | Keybanc | Lowers | Overweight | $62.00 | $66.00 |
| Frank Mitsch | Fermium Research | Lowers | Outperform | $58.00 | $72.00 |
| Arun Viswanathan | RBC Capital | Lowers | Outperform | $61.00 | $67.00 |
| Joel Jackson | BMO Capital | Lowers | Outperform | $64.00 | $70.00 |
| Adam Samuelson | Goldman Sachs | Lowers | Neutral | $56.00 | $65.00 |
| Richard Garchitorena | Wells Fargo | Lowers | Overweight | $66.00 | $73.00 |
| Kristen Owen | Oppenheimer | Announces | Outperform | $67.00 | - |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Corteva. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Corteva compared to the broader market.
- Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Corteva's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.
For valuable insights into Corteva's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Corteva analyst ratings.
About Corteva
Corteva is an agriculture pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop chemicals products. Seeds and crop protection chemicals each make up around half of profits. Although Corteva operates globally, around half of revenue comes from North America.
Unraveling the Financial Story of Corteva
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Negative Revenue Trend: Examining Corteva's financials over 3 months reveals challenges. As of 30 September, 2023, the company experienced a decline of approximately -6.73% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Materials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Corteva's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -12.39%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Corteva's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -1.25%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Corteva's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.74%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Corteva's debt-to-equity ratio is below the industry average at 0.23, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Basics of Analyst Ratings
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
